These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 8690044

  • 1. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F.
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [Abstract] [Full Text] [Related]

  • 2. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.
    Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG.
    J Immunol; 1990 Dec 15; 145(12):4181-4. PubMed ID: 2147937
    [Abstract] [Full Text] [Related]

  • 3. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.
    Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR.
    N Engl J Med; 1987 Aug 27; 317(9):526-32. PubMed ID: 3497347
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption.
    Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM.
    J Immunol; 1987 Mar 01; 138(5):1464-8. PubMed ID: 3492553
    [Abstract] [Full Text] [Related]

  • 5. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.
    Bone; 2006 May 01; 38(5):678-85. PubMed ID: 16309985
    [Abstract] [Full Text] [Related]

  • 6. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
    Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R.
    Cancer Res; 1994 Apr 01; 54(7):1837-42. PubMed ID: 8137298
    [Abstract] [Full Text] [Related]

  • 7. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan 01; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-6 expression and histomorphometry of bones from mice deficient in receptors for interleukin-1 or tumor necrosis factor.
    Vargas SJ, Naprta A, Glaccum M, Lee SK, Kalinowski J, Lorenzo JA.
    J Bone Miner Res; 1996 Nov 01; 11(11):1736-44. PubMed ID: 8915781
    [Abstract] [Full Text] [Related]

  • 9. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma.
    Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B.
    Stem Cells; 1995 Aug 01; 13 Suppl 2():28-34. PubMed ID: 8520508
    [Abstract] [Full Text] [Related]

  • 10. Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells.
    Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J.
    Cancer Res; 1989 Aug 01; 49(15):4242-6. PubMed ID: 2787204
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro.
    Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD.
    J Bone Miner Res; 1989 Feb 01; 4(1):113-8. PubMed ID: 2785743
    [Abstract] [Full Text] [Related]

  • 12. Bone resorption by isolated chick osteoclasts in culture is stimulated by murine spleen cell supernatant fluids (osteoclast-activating factor) and inhibited by calcitonin and prostaglandin E2.
    de Vernejoul MC, Horowitz M, Demignon J, Neff L, Baron R.
    J Bone Miner Res; 1988 Feb 01; 3(1):69-80. PubMed ID: 3264994
    [Abstract] [Full Text] [Related]

  • 13. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
    Burger D, Chicheportiche R, Giri JG, Dayer JM.
    J Clin Invest; 1995 Jul 01; 96(1):38-41. PubMed ID: 7615809
    [Abstract] [Full Text] [Related]

  • 14. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures.
    Devlin RD, Reddy SV, Savino R, Ciliberto G, Roodman GD.
    J Bone Miner Res; 1998 Mar 01; 13(3):393-9. PubMed ID: 9525339
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-1 receptor antagonist inhibits the hypercalcemia mediated by interleukin-1.
    Guise TA, Garrett IR, Bonewald LF, Mundy GR.
    J Bone Miner Res; 1993 May 01; 8(5):583-7. PubMed ID: 8511985
    [Abstract] [Full Text] [Related]

  • 16. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
    François M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT.
    Arthritis Rheum; 2006 Apr 01; 54(4):1233-45. PubMed ID: 16572457
    [Abstract] [Full Text] [Related]

  • 17. Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.
    Hulkower KI, Otis ER, Li J, Ennis BW, Cugier DJ, Bell RL, Carter GW, Glaser KB.
    J Pharmacol Exp Ther; 1997 Feb 01; 280(2):1065-74. PubMed ID: 9023325
    [Abstract] [Full Text] [Related]

  • 18. Biological activity of human epidermal interleukin-1beta: comparison with recombinant human interleukin-1beta.
    Lundqvist EN, Companjen AR, Prens EP, Egelrud T.
    Eur Cytokine Netw; 1998 Mar 01; 9(1):41-6. PubMed ID: 9613676
    [Abstract] [Full Text] [Related]

  • 19. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer.
    Gouze JN, Gouze E, Palmer GD, Liew VS, Pascher A, Betz OB, Thornhill TS, Evans CH, Grodzinsky AJ, Ghivizzani SC.
    Arthritis Res Ther; 2003 Mar 01; 5(5):R301-9. PubMed ID: 12932294
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-1 stimulates the expression of type I and type II interleukin-1 receptors in the rat insulinoma cell line Rinm5F; sequencing a rat type II interleukin-1 receptor cDNA.
    Bristulf J, Gatti S, Malinowsky D, Bjork L, Sundgren AK, Bartfai T.
    Eur Cytokine Netw; 1994 Mar 01; 5(3):319-30. PubMed ID: 7524717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.